Clonal evolution in myelodysplastic syndromes
暂无分享,去创建一个
Satoru Miyano | Yuichi Shiraishi | Martin Dugas | Kenichi Chiba | Gerwin Huls | Sarah Sandmann | Hiroko Tanaka | Seishi Ogawa | Aniek O de Graaf | Bert A van der Reijden | Joop H Jansen | Kenichi Yoshida | S. Miyano | Y. Shiraishi | K. Chiba | S. Ogawa | Kenichi Yoshida | H. Tanaka | M. Dugas | J. Jansen | B. A. van der Reijden | J. Čermák | T. D. de Witte | G. Huls | L. Kroeze | Ruth Knops | M. Massop | M. Stevens-Kroef | S. Sandmann | Jaroslav Cermak | Pedro da Silva-Coelho | T. N. Koorenhof-Scheele | L. T. van de Locht | A. O. de Graaf | N. Blijlevens | P. Muus | Theo de Witte | Leonie I Kroeze | Petra Muus | Pedro da Silva-Coelho | Theresia N Koorenhof-Scheele | Ruth Knops | Louis T van de Locht | Marion Massop | Marian J Stevens-Kroef | Nicole M A Blijlevens | Hiroko Tanaka | A. D. de Graaf
[1] H. Kantarjian,et al. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring , 2018, American journal of hematology.
[2] A. Trumpp,et al. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. , 2016, Blood.
[3] E. van den Berg,et al. Guidelines for genomic array analysis in acquired haematological neoplastic disorders , 2016, Genes, chromosomes & cancer.
[4] M. Stratton,et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents , 2016, Nature Communications.
[5] Christopher A. Miller,et al. Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. , 2016, Blood.
[6] A. Stamatoullas,et al. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. , 2016, Blood.
[7] H. Kantarjian,et al. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring , 2016, American journal of hematology.
[8] G. Mufti,et al. SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment , 2015, Nature Communications.
[9] M. Konopleva,et al. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. , 2015, Leukemia research.
[10] T. Haferlach,et al. Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia , 2015, Haematologica.
[11] A. Baruchel,et al. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network , 2015, Nature Genetics.
[12] D. Longo,et al. Improving Prospects for Targeting RAS. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Hernández‐Rivas,et al. Cryofibrinogenaemia in a patient with multiple myeloma and necrotizing vasculitis , 2015, British journal of haematology.
[14] M. Calasanz,et al. CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q) , 2015, British journal of haematology.
[15] S. Carr,et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS , 2015, Nature.
[16] G. Mufti,et al. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS) , 2015, Leukemia.
[17] G. Mufti,et al. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis. , 2015, The Lancet. Haematology.
[18] K. Döhner,et al. Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q , 2015, Leukemia.
[19] N. McGranahan,et al. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. , 2015, Cancer cell.
[20] M. McCarthy,et al. Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.
[21] S. Gabriel,et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.
[22] O. Abdel-Wahab,et al. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. , 2014, Blood.
[23] G. Vassiliou,et al. Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? , 2014, Disease Models & Mechanisms.
[24] S. Linnarsson,et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. , 2014, Cancer cell.
[25] M. Cazzola,et al. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. , 2014, Blood.
[26] G. Mufti,et al. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q) , 2014, Haematologica.
[27] K. Sailaja,et al. NRAS mutations in de novo acute leukemia: prevalence and clinical significance. , 2014, Indian journal of biochemistry & biophysics.
[28] Thomas J. Hudson,et al. Corrigendum: Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia , 2014, Nature.
[29] Christopher A. Miller,et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. , 2014, Cancer cell.
[30] S. Miyano,et al. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations , 2014, Haematologica.
[31] C Haferlach,et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.
[32] O. Abdel-Wahab,et al. Frequent ASXL 2 mutations in acute myeloid leukemia patients with t ( 8 ; 21 ) / RUNX 1-RUNX 1 T 1 chromosomal translocations , 2014 .
[33] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[34] Z. Estrov,et al. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML , 2013, Leukemia.
[35] S. Miyano,et al. Somatic SETBP1 mutations in myeloid malignancies , 2013, Nature Genetics.
[36] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[37] E Mardis,et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes , 2013, Leukemia.
[38] I. Weissman,et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes , 2013, Proceedings of the National Academy of Sciences.
[39] Joshua F. McMichael,et al. The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.
[40] Ken Chen,et al. Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.
[41] E. van den Berg,et al. Microarray‐based genomic profiling as a diagnostic tool in acute lymphoblastic leukemia , 2011, Genes, chromosomes & cancer.
[42] S. Sugano,et al. Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.
[43] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[44] Eva Hellström-Lindberg,et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Stefan Heinrichs,et al. SNP array analysis in hematologic malignancies: avoiding false discoveries. , 2010, Blood.
[46] L. Shaffer,et al. Comprar ISCN 2009 - An International System for Human Cytogenetic Nomenclature | Marilyn L. Slovak | 9783805589857 | Karger AG , 2009 .
[47] M. E. Duncan,et al. Prevalence and clinical significance , 2005 .
[48] R. Gale,et al. Chronic myeloid leukemia. , 1992, The American journal of medicine.